Biosyent Inc logo

RX - Biosyent Inc Share Price

C$7.9 0.3  4.0%

Last Trade - 16/04/21

Small Cap
Market Cap £59.1m
Enterprise Value £45.3m
Revenue £12.9m
Position in Universe 860th / 2713
Unlock RX Revenue
Relative Strength (%)
1m +5.50%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -6.95%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
15.4 17.9 20.8 21.5 21.4 22.3 26.5 29.8 +7.7%
+18.8 +13.9 +21.1 +10.1 -9.1 -19.4 +31.1 +14.5
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, BiosyentInc. revenues increased 4% to C$22.3M. Net income decreased13% to C$3.8M. Revenues reflect Pharmaceutical Businesssegment increase of 5% to C$21.5M. Net income was offset byAdvertising, promotion and sales people increase of 44% toC$4.1M (expense), Employee Costs increase of 11% to C$2.8M(expense). Basic Earnings per Share excluding ExtraordinaryItems decreased from C$0.31 to C$0.29.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for RX
Graphical History


RX Revenue Unlock RX Revenue

Net Income

RX Net Income Unlock RX Revenue

Normalised EPS

RX Normalised EPS Unlock RX Revenue

PE Ratio Range

RX PE Ratio Range Unlock RX Revenue

Dividend Yield Range

RX Dividend Yield Range Unlock RX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
RX EPS Forecasts Unlock RX Revenue
Profile Summary

BioSyent Inc. is a specialty pharmaceutical company. The Company, through its subsidiary, BioSyent Pharma Inc., acquires or in-licenses and develops pharmaceutical products for sale in Canada and certain international markets. It has four business units: the Community and Women's Health Unit, which commercializes pharmaceutical products focused on improving family and women's health; the Hospital Business Unit, which sells pharmaceutical products to hospitals and hospital specialists; the International Pharmaceutical Unit, and the Legacy Business. Its products include FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Aguettant System and Cysview. FeraMAX 150 is an oral hematinic indicated for the prevention and treatment of iron deficiency anemia. Cathejell is indicated for surface anesthesia and lubrication for various procedures. RepaGyn helps relieve dryness and promotes healing of the vaginal mucosa. It also manufactures and markets Protect-It, a non-toxic product.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated May 19, 1999
Public Since May 22, 1981
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Pharmaceuticals
Exchange TSX Venture Exchange
Shares in Issue 12,937,366
Free Float (0.0%)
Eligible for
RX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for RX
Upcoming Events for RX
Frequently Asked Questions for Biosyent Inc
What is the Biosyent Inc share price?

As of 16/04/21, shares in Biosyent Inc are trading at C$7.9, giving the company a market capitalisation of £59.1m. This share price information is delayed by 15 minutes.

How has the Biosyent Inc share price performed this year?

Shares in Biosyent Inc are currently trading at C$7.9 and the price has moved by 90.36% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Biosyent Inc price has moved by 41.47% over the past year.

What are the analyst and broker recommendations for Biosyent Inc?

Of the analysts with advisory recommendations for Biosyent Inc, there are there are currently 0 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Biosyent Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Biosyent Inc next release its financial results?

Biosyent Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Biosyent Inc dividend yield?

Biosyent Inc does not currently pay a dividend.

Does Biosyent Inc pay a dividend?

Biosyent Inc does not currently pay a dividend.

When does Biosyent Inc next pay dividends?

Biosyent Inc does not currently pay a dividend.

How do I buy Biosyent Inc shares?

To buy shares in Biosyent Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Biosyent Inc?

Shares in Biosyent Inc are currently trading at C$7.9, giving the company a market capitalisation of £59.1m.

Where are Biosyent Inc shares listed? Where are Biosyent Inc shares listed?

Here are the trading details for Biosyent Inc:

Country of listing: Canada
Exchange: CVE
Ticker Symbol: RX
What kind of share is Biosyent Inc?

Based on an overall assessment of its quality, value and momentum, Biosyent Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Biosyent Inc share price forecast 2021?

Shares in Biosyent Inc are currently priced at C$7.9. At that level they are trading at 5.06% premium to the analyst consensus target price of 0.00.

Analysts covering Biosyent Inc currently have a consensus Earnings Per Share (EPS) forecast of 0.38 for the next financial year.

How can I tell whether the Biosyent Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biosyent Inc. Over the past six months, the relative strength of its shares against the market has been -4.26%. At the current price of C$7.9, shares in Biosyent Inc are trading at 12.96% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Biosyent Inc PE Ratio?

The Biosyent Inc PE ratio based on its reported earnings over the past 12 months is 27.26. The shares are currently trading at C$7.9.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Biosyent Inc?

Biosyent Inc's management team is headed by:

Rene Goehrum - CHM
Kevin Wilson - VPR
Larry Andrews - DRC
Sara Elford - DRC
Joseph Arcuri - DRC
Robert March - CFO
Sharan Raghubir - DRC
Navid Ashrafi - DRC
Who are the major shareholders of Biosyent Inc?

Here are the top five shareholders of Biosyent Inc based on the size of their shareholding:

Goehrum (René Christopher) Individual Investor
Percentage owned: 13.05% (1.69m shares)
CI Investments Inc. Investment Advisor/Hedge Fund
Percentage owned: 9.74% (1.26m shares)
Cambridge Pure Canadian Equity Fund Mutual Fund
Percentage owned: 7.73% (1,000k shares)
Lockhard (Peter Douglas) Individual Investor
Percentage owned: 5.06% (654k shares)
Aquiam Partners, Ltd. Corporation
Percentage owned: 3.86% (500k shares)
Similar to RX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.